MGNX Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against MacroGenics, Inc. for allegedly making false and misleading statements regarding the safety profile of its drug vobramitamab duocarmazine during the TAMARACK Phase 2 study [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Maryland on behalf of investors who purchased MacroGenics stock or sold puts between March 7, 2024, and May 9, 2024 [1]. - The lead plaintiff deadline for the lawsuit is September 24, 2024 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants created a materially misleading impression regarding the safety profile of vobramitamab duocarmazine and the overall data from the Phase 2 TAMARACK study [2]. Group 3: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain an absent class member [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [3]. Group 4: Firm Information - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4].